tolazoline has been researched along with Infantile Respiratory Distress Syndrome in 22 studies
Tolazoline: A vasodilator that apparently has direct actions on blood vessels and also increases cardiac output. Tolazoline can interact to some degree with histamine, adrenergic, and cholinergic receptors, but the mechanisms of its therapeutic effects are not clear. It is used in treatment of persistent pulmonary hypertension of the newborn.
tolazoline : A member of the class of imidazoles that is 4,5-dihydro-1H-imidazole substituted by a benzyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The clinical appearance of these six neonates included respiratory distress, cyanosis, and/or apnea." | 3.66 | beta-hemolytic streptococcal infection appearing as persistent fetal circulation. ( Desai, R; Farooki, ZQ; Shankaran, S, 1982) |
| "Tolazoline is an effective treatment of severe resistant hypoxemia in preterm infants who are already on vigorous ventilatory support." | 1.31 | Efficacy and safety of tolazoline for treatment of severe hypoxemia in extremely preterm infants. ( Bada, HS; Korones, SB; Nuntnarumit, P; Yang, W, 2002) |
| "Pulmonary hypertension was associated with nonresponse to surfactant in six premature infants with respiratory distress syndrome." | 1.29 | Pulmonary hypertension in respiratory distress syndrome. ( Golan, A; Shinwell, ES; Zalzstein, E; Zmora, E, 1995) |
| "Infants with congenital diaphragmatic hernia (CDH) die, because their lungs are hypoplastic and their pulmonary vascular resistance remains elevated after birth." | 1.29 | High-frequency ventilation in newborn lambs after intra-uterine creation of diaphragmatic hernia. ( Chourrout, Y; Ghnassia, D; Harf, A; Isabey, D; Jaubert, F; Martelli, H; Piquet, J; Revillon, Y; Sidi, D, 1993) |
| "Tolazoline was given to 14 infants of whom ten showed an improvement in oxygenation; dopamine was given to three infants who were oliguric." | 1.27 | Management of infants with severe respiratory failure and persistence of the fetal circulation, without hyperventilation. ( James, E; James, LS; Kilchevsky, E; Wung, JT, 1985) |
| "Thirty-nine critically ill infants with pulmonary disease received tolazoline because of severe hypoxemia refractory to administration of 100% O2 and mechanical ventilation." | 1.26 | Refractory hypoxemia associated with neonatal pulmonary disease: the use and limitations of tolazoline. ( Ariagno, RL; Beets, CL; Darnall, RA; Johnson, JD; Kasting, DS; Malachowski, N; Stevenson, DK; Sunshine, P, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 18 (81.82) | 18.7374 |
| 1990's | 2 (9.09) | 18.2507 |
| 2000's | 2 (9.09) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ostrea, EM | 1 |
| Villanueva-Uy, ET | 1 |
| Natarajan, G | 1 |
| Uy, HG | 1 |
| Cohen, RS | 1 |
| Stevenson, DK | 2 |
| Malachowski, N | 2 |
| Ariagno, RL | 2 |
| Johnson, JD | 2 |
| Sunshine, P | 2 |
| Batton, DG | 1 |
| Maisels, MJ | 1 |
| Fripp, RR | 1 |
| Heald, JI | 1 |
| Shankaran, S | 1 |
| Farooki, ZQ | 1 |
| Desai, R | 1 |
| Bloss, RS | 1 |
| Aranda, JV | 1 |
| Beardmore, HE | 1 |
| Oh, W | 1 |
| Tulassay, T | 1 |
| Kiszel, J | 2 |
| Csömör, S | 1 |
| Machay, T | 2 |
| Mártha, I | 1 |
| Hegyi, T | 1 |
| Hiatt, IM | 1 |
| Golan, A | 1 |
| Zalzstein, E | 1 |
| Zmora, E | 1 |
| Shinwell, ES | 1 |
| Revillon, Y | 1 |
| Sidi, D | 1 |
| Chourrout, Y | 1 |
| Martelli, H | 1 |
| Ghnassia, D | 1 |
| Piquet, J | 1 |
| Isabey, D | 1 |
| Harf, A | 1 |
| Jaubert, F | 1 |
| Nuntnarumit, P | 1 |
| Korones, SB | 1 |
| Yang, W | 1 |
| Bada, HS | 1 |
| Kasting, DS | 1 |
| Darnall, RA | 1 |
| Beets, CL | 1 |
| de Geeter, B | 1 |
| Messer, J | 1 |
| Benoit, M | 1 |
| Willard, D | 1 |
| Monin, P | 1 |
| Vert, P | 1 |
| Moodie, DS | 1 |
| Kleinberg, F | 1 |
| Telander, RL | 1 |
| Kaye, MP | 1 |
| Feldt, RH | 1 |
| Andrews, AF | 1 |
| Nixon, CA | 1 |
| Cilley, RE | 1 |
| Roloff, DW | 1 |
| Bartlett, RH | 1 |
| Meadow, W | 1 |
| Benn, A | 1 |
| Giardini, N | 1 |
| Hageman, J | 1 |
| Berger, S | 1 |
| Brereton, RJ | 1 |
| Kumar, D | 1 |
| Spitz, L | 1 |
| Seri, I | 1 |
| Heath, RE | 1 |
| Wung, JT | 1 |
| James, LS | 1 |
| Kilchevsky, E | 1 |
| James, E | 1 |
| Stern, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| TOTAL TRIAL: Randomized Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) Versus Expectant Management During Pregnancy in Fetuses With Left-Sided and Isolated Congenital Diaphragmatic Hernia and Moderate Pulmonary Hypoplasia[NCT02875860] | Phase 2 | 5 participants (Actual) | Interventional | 2017-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
How many days from birth until the surgery is performed to repair the defect. (NCT02875860)
Timeframe: From the time of birth until discharge from the NICU
| Intervention | days (Median) |
|---|---|
| Standardized Postnatal Care (Expectant) | 1 |
| Prenatal Intervention (FETO) | 2.5 |
The number of days until full enteral feeding (NCT02875860)
Timeframe: At hospital discharge, an average of 1.5 months
| Intervention | days (Median) |
|---|---|
| Standardized Postnatal Care (Expectant) | 27 |
| Prenatal Intervention (FETO) | 29.5 |
Need for extracorporeal membrane oxygenation (ECMO) in the neonatal period (NCT02875860)
Timeframe: Neonatal period (during the first 4 weeks of life)
| Intervention | Participants (Count of Participants) |
|---|---|
| Standardized Postnatal Care (Expectant) | 1 |
| Prenatal Intervention (FETO) | 2 |
Presence of reflux above 1/3 of esophagus on clinically indicated radiologic exam (NCT02875860)
Timeframe: At the time of discharge from the NICU, an average of 1.5 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Standardized Postnatal Care (Expectant) | 1 |
| Prenatal Intervention (FETO) | 0 |
Measured as presence in neonate during first month by MRI and/or ultrasound. (NCT02875860)
Timeframe: During first month of life
| Intervention | Participants (Count of Participants) |
|---|---|
| Standardized Postnatal Care (Expectant) | 0 |
| Prenatal Intervention (FETO) | 0 |
As measured by presence in medical record (NCT02875860)
Timeframe: During the first 4 weeks of life (neonatal period)
| Intervention | Participants (Count of Participants) |
|---|---|
| Standardized Postnatal Care (Expectant) | 1 |
| Prenatal Intervention (FETO) | 0 |
Length of stay in the neonatal intensive care unit measured in days (NCT02875860)
Timeframe: At the time of discharge from the NICU, an average of 1.5 months
| Intervention | days (Median) |
|---|---|
| Standardized Postnatal Care (Expectant) | 39 |
| Prenatal Intervention (FETO) | 53 |
As measured by presence in medical record ≤ 2 months postnatally by ultrasound (yes/no) (NCT02875860)
Timeframe: During first 2 months of life
| Intervention | Participants (Count of Participants) |
|---|---|
| Standardized Postnatal Care (Expectant) | 0 |
| Prenatal Intervention (FETO) | 0 |
Occurrence of severe pulmonary hypertension in the neonatal period. (NCT02875860)
Timeframe: During the first 4 weeks of life (neonatal period).
| Intervention | Participants (Count of Participants) |
|---|---|
| Standardized Postnatal Care (Expectant) | 2 |
| Prenatal Intervention (FETO) | 2 |
The number of survivors requiring supplemental oxygen at 6 months of age (NCT02875860)
Timeframe: At 6 months of age
| Intervention | Participants (Count of Participants) |
|---|---|
| Standardized Postnatal Care (Expectant) | 1 |
| Prenatal Intervention (FETO) | 1 |
The null hypothesis to be tested is that there is no difference in survival between fetuses managed expectantly during pregnancy versus those undergoing antenatal therapy (FETO). (NCT02875860)
Timeframe: At hospital discharge, an average of 1.5 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Standardized Postnatal Care (Expectant) | 1 |
| Prenatal Intervention (FETO) | 3 |
Postnatal grade classification presence of grade III or higher using standardized system (yes/no) (NCT02875860)
Timeframe: At the time of discharge from the NICU, an average of 1.5 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Standardized Postnatal Care (Expectant) | 0 |
| Prenatal Intervention (FETO) | 0 |
The number of participants that survived to 24 months of age (NCT02875860)
Timeframe: At 24 months of age
| Intervention | Participants (Count of Participants) |
|---|---|
| Standardized Postnatal Care (Expectant) | 1 |
| Prenatal Intervention (FETO) | 3 |
The number of participants who had a patch used in the repair of the CDH defect. (NCT02875860)
Timeframe: At the time of the surgical repair postnatally, up to 3 days postnatal
| Intervention | Participants (Count of Participants) |
|---|---|
| Standardized Postnatal Care (Expectant) | 2 |
| Prenatal Intervention (FETO) | 2 |
Length of time participants required ventilator support measured in days. (NCT02875860)
Timeframe: During the first 4 weeks of life (neonatal period)
| Intervention | days (Median) |
|---|---|
| Standardized Postnatal Care (Expectant) | 18 |
| Prenatal Intervention (FETO) | 21 |
2 reviews available for tolazoline and Infantile Respiratory Distress Syndrome
| Article | Year |
|---|---|
Persistent pulmonary hypertension of the newborn: pathogenesis, etiology, and management.
Topics: Extracorporeal Membrane Oxygenation; Humans; Infant, Newborn; Persistent Fetal Circulation Syndrome; | 2006 |
Therapy of the respiratory distress syndrome.
Topics: Body Temperature Regulation; Catecholamines; Fibrinolytic Agents; Histamine H1 Antagonists; Homeosta | 1972 |
20 other studies available for tolazoline and Infantile Respiratory Distress Syndrome
| Article | Year |
|---|---|
Late morbidity among survivors of respiratory failure treated with tolazoline.
Topics: Child, Preschool; Developmental Disabilities; Humans; Infant, Newborn; Respiratory Distress Syndrome | 1980 |
Arterial hyperoxia in a newborn infant with transposition of the great vessels.
Topics: Blood Gas Analysis; Cyanosis; Female; Humans; Hyperbaric Oxygenation; Infant, Newborn; Infant, Newbo | 1982 |
beta-hemolytic streptococcal infection appearing as persistent fetal circulation.
Topics: Apnea; Female; Humans; Infant, Newborn; Infant, Newborn, Diseases; Infant, Premature, Diseases; Male | 1982 |
Vasodilator response and prediction of survival in congenital diaphragmatic hernia.
Topics: Hernia, Diaphragmatic; Hernias, Diaphragmatic, Congenital; Humans; Infant, Newborn; Oxygen; Persiste | 1981 |
Renal functions and clinical disorders in the neonate.
Topics: Acute Kidney Injury; Anti-Bacterial Agents; Asphyxia Neonatorum; Furosemide; Humans; Indomethacin; I | 1981 |
[Tolazoline-HCl in cardio-respiratory adaptation of newborns with respiratory distress syndrome (author's transl)].
Topics: Blood Circulation; Humans; Infant, Newborn; Oxygen; Parasympathomimetics; Partial Pressure; Respirat | 1981 |
Tolazoline and dopamine therapy in neonatal hypoxia and pulmonary vasospasm.
Topics: Dopamine; Female; Humans; Hypoxia; Infant, Newborn; Infant, Newborn, Diseases; Infant, Premature, Di | 1980 |
Pulmonary hypertension in respiratory distress syndrome.
Topics: Humans; Hypertension, Pulmonary; Infant, Newborn; Infant, Premature, Diseases; Respiratory Distress | 1995 |
High-frequency ventilation in newborn lambs after intra-uterine creation of diaphragmatic hernia.
Topics: Animals; Animals, Newborn; Female; Hemodynamics; Hernia, Diaphragmatic; Hernias, Diaphragmatic, Cong | 1993 |
Efficacy and safety of tolazoline for treatment of severe hypoxemia in extremely preterm infants.
Topics: Blood Pressure; Blood Proteins; Carbon Dioxide; Dose-Response Relationship, Drug; Female; Gestationa | 2002 |
Refractory hypoxemia associated with neonatal pulmonary disease: the use and limitations of tolazoline.
Topics: Carbon Dioxide; Humans; Hyaline Membrane Disease; Hypoxia; Infant, Newborn; Infant, Newborn, Disease | 1979 |
Right-to-left ductal shunt and transcutaneous PO2.
Topics: Blood Gas Analysis; Diagnosis, Differential; Ductus Arteriosus, Patent; Heart Defects, Congenital; H | 1979 |
[The persistence of foetal circulation. Neonatal pulmonary arterial hypertension. Favourable action of tolazoline (author's transl)].
Topics: Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Infant, Newborn; Infant, Newborn, Diseas | 1978 |
Tolazoline as adjuvant therapy for ill neonates with pulmonary hypoperfusion.
Topics: Female; Humans; Infant, Newborn; Infant, Newborn, Diseases; Lung Diseases; Male; Respiratory Distres | 1978 |
One- to three-year outcome for 14 neonatal survivors of extracorporeal membrane oxygenation.
Topics: Cerebral Hemorrhage; Developmental Disabilities; Electroencephalography; Extracorporeal Circulation; | 1986 |
Clinical correlates do not predict PaO2 response after tolazoline administration in hypoxic newborns.
Topics: Blood Pressure; Humans; Hypoxia; Infant, Newborn; Oxygen; Partial Pressure; Persistent Fetal Circula | 1986 |
Diaphragmatic hernia in neonate.
Topics: Carbon Dioxide; Dopamine; Hernia, Diaphragmatic; Hernias, Diaphragmatic, Congenital; Humans; Infant, | 1985 |
High-frequency oscillatory ventilation (HFOV) in the treatment of neonatal respiratory disturbances: case reports of two infants.
Topics: Carbon Dioxide; Humans; Humidity; Hyaline Membrane Disease; Infant, Newborn; Infant, Premature; Male | 1985 |
Vasospasm in the neonate: response to tolazoline infusion.
Topics: Catheters, Indwelling; Humans; Infant, Newborn; Infant, Premature, Diseases; Infusions, Intra-Arteri | 1986 |
Management of infants with severe respiratory failure and persistence of the fetal circulation, without hyperventilation.
Topics: Birth Weight; Dopamine; Humans; Hyperventilation; Infant, Newborn; Intubation, Intratracheal; Meconi | 1985 |